Search Results

There are 6992 results for: content related to: Viral kinetics in genotype 1 chronic hepatitis C patients during therapy with 2 different doses of peginterferon alfa-2b plus ribavirin

  1. Estimating the likelihood of sustained virological response in chronic hepatitis C therapy

    Journal of Viral Hepatitis

    Volume 18, Issue 4, April 2011, Pages: e81–e90, S. Mauss, D. Hueppe, C. John, J Goelz, R. Heyne, B. Moeller, R. Link, G. Teuber, A. Herrmann, M. Spelter, S. Wollschlaeger, A. Baumgarten, K.-G. Simon, N. Dikopoulos and T. Witthoeft

    Version of Record online : 16 SEP 2010, DOI: 10.1111/j.1365-2893.2010.01372.x

  2. You have free access to this content
    Hepatitis C virus: How genetic variability affects pathobiology of disease

    Journal of Gastroenterology and Hepatology

    Volume 26, Issue s1, January 2011, Pages: 83–95, Kazuaki Chayama and C Nelson Hayes

    Version of Record online : 4 JAN 2011, DOI: 10.1111/j.1440-1746.2010.06550.x

  3. Peginterferon alfa-2a versus Peginterferon alfa-2b as Initial Treatment of Hepatitis C Virus Infection: A Cost-Utility Analysis from the Perspective of the Veterans Affairs Health Care System

    Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy

    Volume 27, Issue 6, June 2007, Pages: 813–824, Wei-Shi Yeh, Edward P. Armstrong, Grant H. Skrepnek and Daniel C. Malone

    Version of Record online : 6 JAN 2012, DOI: 10.1592/phco.27.6.813

  4. The Effect of Multiple Doses of Peginterferon alfa-2b on the Steady-State Pharmacokinetics of Methadone in Patients With Chronic Hepatitis C Undergoing Methadone Maintenance Therapy

    The Journal of Clinical Pharmacology

    Volume 47, Issue 5, May 2007, Pages: 604–612, Dr Samir K. Gupta, Dr Edward Sellers, Dr Eugene Somoza, Dr Luis Angles, Dr Karen Kolz and Dr David L. Cutler

    Version of Record online : 7 MAR 2013, DOI: 10.1177/0091270007299760

  5. You have free access to this content
    Peginterferon alfa-2a/ribavirin in hepatitis C virus patients nontolerant or nonresponsive to peginterferon alfa-2b/ribavirin

    Alimentary Pharmacology & Therapeutics

    Volume 27, Issue 5, March 2008, Pages: 433–440, V. K. RUSTGI, S. ESPOSITO, F. M. HAMZEH and M. L. SHIFFMAN

    Version of Record online : 10 DEC 2007, DOI: 10.1111/j.1365-2036.2007.03587.x

  6. You have free access to this content
    Diagnosis, management, and treatment of hepatitis C: An update

    Hepatology

    Volume 49, Issue 4, April 2009, Pages: 1335–1374, Marc G. Ghany, Doris B. Strader, David L. Thomas and Leonard B. Seeff

    Version of Record online : 2 DEC 2008, DOI: 10.1002/hep.22759

  7. Current Therapies for Chronic Hepatitis C

    Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy

    Volume 31, Issue 1, January 2011, Pages: 92–111, McKenzie C. Ferguson

    Version of Record online : 6 JAN 2012, DOI: 10.1592/phco.31.1.92

  8. You have free access to this content
    Pharmacodynamics of peginterferon alfa-2a and peginterferon alfa-2b in interferon-naïve patients with chronic hepatitis C: a randomized, controlled study

    Alimentary Pharmacology & Therapeutics

    Volume 26, Issue 3, August 2007, Pages: 369–376, R. BRUNO, P. SACCHI, C. SCAGNOLARI, F. TORRIANI, L. MAIOCCHI, S. PATRUNO, F. BELLOMI, G. FILICE and G. ANTONELLI

    Version of Record online : 29 MAY 2007, DOI: 10.1111/j.1365-2036.2007.03392.x

  9. Boceprevir: A Novel NS3/4 Protease Inhibitor for the Treatment of Hepatitis C

    Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy

    Volume 32, Issue 2, February 2012, Pages: 173–190, Olga M. Klibanov, Stephen B. Vickery, Jacqueline L. Olin, Lisa S. Smith and Shannon H. Williams

    Version of Record online : 30 JAN 2012, DOI: 10.1002/PHAR.1046

  10. Telaprevir: A Novel NS3/4 Protease Inhibitor for the Treatment of Hepatitis C

    Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy

    Volume 31, Issue 10, October 2011, Pages: 951–974, Olga M. Klibanov, Shannon H. Williams, Lisa S. Smith, Jacqueline L. Olin and Stephen B. Vickery

    Version of Record online : 6 JAN 2012, DOI: 10.1592/phco.31.10.951

  11. You have free access to this content
    Peginterferon alpha-2a versus peginterferon alpha-2b for chronic hepatitis C

    Intervention Review

    The Cochrane Library

    Goran Hauser, Tahany Awad, Kristian Thorlund, Davor Štimac, Mahasen Mabrouk and Christian Gluud

    Published Online : 28 FEB 2014, DOI: 10.1002/14651858.CD005642.pub3

  12. You have free access to this content
    Abstracts 1020 to 1278

    Hepatology

    Volume 42, Issue S1, October 2005, Pages: 598A–702A,

    Version of Record online : 5 OCT 2005, DOI: 10.1002/hep.20927

  13. Follow-up of Adverse Drug Reactions from Peginterferon alfa-2b—Ribavirin Therapy

    Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy

    Volume 24, Issue 11, November 2004, Pages: 1546–1553, Dr. Haleh Bagheri, Dr. Atoussa Fouladi, Dr. Karl Barange, Dr. Maryse Lapeyre-Mestre, Dr. Jean-Louis Payen, Dr. Jean Louis Montastruc and Dr. Jean-Pierre Vinel

    Version of Record online : 16 JAN 2012, DOI: 10.1592/phco.24.16.1546.50947

  14. You have free access to this content
    A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C

    Hepatology

    Volume 34, Issue 2, August 2001, Pages: 395–403, Karen L. Lindsay, Christian Trepo, Tobias Heintges, Mitchell L. Shiffman, Stuart C. Gordon, John C. Hoefs, Eugene R. Schiff, Zachary D. Goodman, Mark Laughlin, Ruji Yao and Janice K. Albrecht

    Version of Record online : 30 DEC 2003, DOI: 10.1053/jhep.2001.26371

  15. You have free access to this content
    Results of the IDEAL trial: “Mirror, mirror on the wall … Which's the fairest peg-interferon of them all?”

    Hepatology

    Volume 50, Issue 6, December 2009, Pages: 2034–2037, Julian Schulze zur Wiesch and Ansgar W. Lohse

    Version of Record online : 20 NOV 2009, DOI: 10.1002/hep.23376

  16. You have free access to this content
    Peginterferon alpha-2a is associated with higher sustained virological response than peginterferon alfa-2b in chronic hepatitis C: Systematic review of randomized trials

    Hepatology

    Volume 51, Issue 4, April 2010, Pages: 1176–1184, Tahany Awad, Kristian Thorlund, Goran Hauser, Davor Stimac, Mahasen Mabrouk and Christian Gluud

    Version of Record online : 23 DEC 2009, DOI: 10.1002/hep.23504

  17. You have free access to this content
    Abstracts 210 to 431

    Hepatology

    Volume 46, Issue S1, October 2007, Pages: 331A–430A,

    Version of Record online : 19 SEP 2007, DOI: 10.1002/hep.22017

  18. Efficacy and tolerability of peginterferon alfa-2a or alfa-2b plus ribavirin in the daily routine treatment of patients with chronic hepatitis C in Germany: The PRACTICE Study

    Journal of Viral Hepatitis

    Volume 17, Issue 7, July 2010, Pages: 459–468, T. Witthoeft, D. Hueppe, C. John, J. Goelz, R. Heyne, B. Moeller, G. Teuber, S. Wollschlaeger, A. Baumgarten, K.-G. Simon, G. Moog, N. Dikopoulos and S. Mauss

    Version of Record online : 11 FEB 2010, DOI: 10.1111/j.1365-2893.2009.01255.x

  19. You have free access to this content
    HCV Therapeutics: Approved Agents

    Hepatology

    Volume 58, Issue S1, October 2013, Pages: 1091A–1168A,

    Version of Record online : 15 OCT 2013, DOI: 10.1002/hep.26880

  20. You have free access to this content
    Improved outcomes in patients with hepatitis C with difficult-to-treat characteristics: Randomized study of higher doses of peginterferon α-2a and ribavirin

    Hepatology

    Volume 48, Issue 4, October 2008, Pages: 1033–1043, Michael W. Fried, Donald M. Jensen, Maribel Rodriguez-Torres, Lisa M. Nyberg, Adrian M. Di Bisceglie, Timothy R. Morgan, Paul J. Pockros, Amy Lin, Lisa Cupelli, Frank Duff, Ka Wang and David R. Nelson

    Version of Record online : 9 JUN 2008, DOI: 10.1002/hep.22448